BioInvent

BioInvent is a clinical-stage company focused on developing novel, first-class immunomodulatory antibodies for cancer treatment, aiming to meet the demand for new drugs with the potential to significantly improve outcomes for cancer patients. BioInvent's robust and proven screening tool, FIRST™, along with its proprietary antibody library, n-CoDeR®, can simultaneously identify the most relevant target structures and the antibodies that bind to them. This has led to the discovery of numerous promising new drug candidates within the company’s own pipeline as well as through licensing and partnership collaborations. BioInvent's state-of-the-art manufacturing facilities have the capacity to produce the antibodies required for the company’s preclinical research and clinical trials, providing a significant developmental advantage by offering a fast and cost-effective path forward compared to relying on external resources.